Unicycive Therapeutics
UNCY | NASDAQ
$3.70
+$0.15 (+4.23%)
At close: Nov 16, 2026, 4:00 PM ET
$3.70
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:34 PM ET
+4.23%
(1D)No price chart data available for 1D timeframe.
Rating
37
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #617/1021 (Top 60%)
Key Statistics
Market Data
Market Cap $101.35M
1D Range
3.55 3.76
52W Range
3.36 8.56
Valuation (TTM)
PE -2.22
PB 1.90
EV/EBITDA -1.18
Valuation (NTM)
Forward PE 2.66
Forward PEG 0.16
Price Target $22.00
Cash Flow
FCF Yield -27.5%
SBC Adj. FCF Yield -31.8%
SBC Impact -15.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -150.0% |
-50.0%
Dil EPS 3Y | 5Y 52.2% |
39.0%
FCF 3Y | 5Y -11.2% |
-21.3%
Returns
ROA -48.9%
ROE -88.8%
ROIC -61.4%
Financial Health
Net Cash
$61.43M
Current Ratio 3.81
Interest Coverage -789.12
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyp...
Sector Healthcare
Industry Biotechnology
Employees 21
IPO Date Jul 12, 2021
Website www.unicycive.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$22.00
Upside
+494.59%
Buy (5)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove UNCY